adplus-dvertising
Connect with us

Business

New AstraZeneca report says vaccine 76 per cent effective in preventing symptoms

Published

 on

Drug giant AstraZeneca updated its data on how well its coronavirus vaccine works, saying late Wednesday the vaccine showed 76 per cent efficacy against symptomatic coronavirus disease and 100 per cent efficacy against severe or critical disease or the need for hospitalization.

The vaccine was 85 per cent effective in preventing symptoms in volunteers 65 and older, the company said.

The numbers are not terribly different from data the company released in a statement Monday. As with Monday’s data, the company has released them via news release and not in a peer-reviewed report or as a formal submission for US Food and Drug Administration review.

“The primary analysis is consistent with our previously released interim analysis, and confirms that our COVID-19 vaccine is highly effective in adults, including those aged 65 years and over. We look forward to filing our regulatory submission for Emergency Use Authorization in the US and preparing for the rollout of millions of doses across America,” Mene Pangalos, executive vice president for biopharmaceuticals research for the company, said in a statement.

On Tuesday, the independent Data and Safety Monitoring Board (DSMB) that reviews data from multiple COVID-19 vaccine candidates expressed concern over AstraZeneca’s announcements on its latest findings, and, unusually, the National Institute of Allergy and Infectious Diseases publicly announced those concerns.

“The DSMB expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data,” the NIAID, which has helped AstraZeneca run trials in the U.S., said.

“We urge the company to work with the DSMB to review the efficacy data and ensure the most accurate, up-to-date efficacy data be made public as quickly as possible.”

On Monday, AstraZeneca said its COVID-19 vaccine showed 79% efficacy against symptomatic disease and 100% efficacy against severe disease and hospitalization.

The trial of 32,449 volunteers in the U.S., Peru and Chile showed people who got the vaccine were 76% less likely to have any symptoms of coronavirus compared to the one-third of participants who got placebo. The vaccine is given as two doses, four weeks apart.

As with other vaccine trials, the company was looking to see how many vaccinated people got COVID-19 symptoms as compared to unvaccinated people.

“There were 190 cases in the primary analysis. There are 14 additional possible or probable cases to be adjudicated so the total number of cases and the point estimate may fluctuate slightly,” the company said.

“AstraZeneca will also submit the primary analysis for peer-reviewed publication in the coming weeks.”

And as with other coronavirus vaccine trials, the volunteers were not regularly tested for COVID-19, so it’s not known how many may have gotten asymptomatic infections.

“A key secondary endpoint, preventing severe or critical disease and hospitalization, demonstrated 100% efficacy. There were eight cases of severe COVID-19 observed in the primary analysis with all of those cases in the placebo group,” the company said.

“The vaccine was well tolerated, and no safety concerns related to the vaccine were identified.”

NIAID director Dr. Anthony Fauci earlier this week called the company’s release of premature data an “unforced error” — a sports term meaning it was their own mistake.

He told ABC’s Good Morning America on Tuesday that the AstraZeneca vaccine “is very likely a very good vaccine,” and this situation does nothing but cast doubt about the vaccines and maybe contribute to vaccine hesitancy.

Fauci said that this was not necessary and that the data are “really quite good, but when they put it into the press release, it wasn’t completely accurate.”

AstraZeneca, which developed the vaccine with Britain’s University of Oxford, has struggled for acceptance of its vaccine.

It was the first immunization out of the gate in the western world, going into the arms of volunteers on Jan. 4. But AstraZeneca’s development of the vaccine has hit multiple bumps, from news that two volunteers developed neurological symptoms last fall to a stall in the rollout of the vaccine in several European countries amid fears it might have caused blood clots.

The European Medicines Agency has since said there’s no evidence the vaccine can cause blood clots.

Source:- CTV News

Source link

Continue Reading

Business

Roots sees room for expansion in activewear, reports $5.2M Q2 loss and sales drop

Published

 on

 

TORONTO – Roots Corp. may have built its brand on all things comfy and cosy, but its CEO says activewear is now “really becoming a core part” of the brand.

The category, which at Roots spans leggings, tracksuits, sports bras and bike shorts, has seen such sustained double-digit growth that Meghan Roach plans to make it a key part of the business’ future.

“It’s an area … you will see us continue to expand upon,” she told analysts on a Friday call.

The Toronto-based retailer’s push into activewear has taken shape over many years and included several turns as the official designer and supplier of Team Canada’s Olympic uniform.

But consumers have had plenty of choice when it comes to workout gear and other apparel suited to their sporting needs. On top of the slew of athletic brands like Nike and Adidas, shoppers have also gravitated toward Lululemon Athletica Inc., Alo and Vuori, ramping up competition in the activewear category.

Roach feels Roots’ toehold in the category stems from the fit, feel and following its merchandise has cultivated.

“Our product really resonates with (shoppers) because you can wear it through multiple different use cases and occasions,” she said.

“We’ve been seeing customers come back again and again for some of these core products in our activewear collection.”

Her remarks came the same day as Roots revealed it lost $5.2 million in its latest quarter compared with a loss of $5.3 million in the same quarter last year.

The company said the second-quarter loss amounted to 13 cents per diluted share for the quarter ended Aug. 3, the same as a year earlier.

In presenting the results, Roach reminded analysts that the first half of the year is usually “seasonally small,” representing just 30 per cent of the company’s annual sales.

Sales for the second quarter totalled $47.7 million, down from $49.4 million in the same quarter last year.

The move lower came as direct-to-consumer sales amounted to $36.4 million, down from $37.1 million a year earlier, as comparable sales edged down 0.2 per cent.

The numbers reflect the fact that Roots continued to grapple with inventory challenges in the company’s Cooper fleece line that first cropped up in its previous quarter.

Roots recently began to use artificial intelligence to assist with daily inventory replenishments and said more tools helping with allocation will go live in the next quarter.

Beyond that time period, the company intends to keep exploring AI and renovate more of its stores.

It will also re-evaluate its design ranks.

Roots announced Friday that chief product officer Karuna Scheinfeld has stepped down.

Rather than fill the role, the company plans to hire senior level design talent with international experience in the outdoor and activewear sectors who will take on tasks previously done by the chief product officer.

This report by The Canadian Press was first published Sept. 13, 2024.

Companies in this story: (TSX:ROOT)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

Talks on today over HandyDART strike affecting vulnerable people in Metro Vancouver

Published

 on

 

VANCOUVER – Mediated talks between the union representing HandyDART workers in Metro Vancouver and its employer, Transdev, are set to resume today as a strike that has stopped most services drags into a second week.

No timeline has been set for the length of the negotiations, but Joe McCann, president of the Amalgamated Transit Union Local 1724, says they are willing to stay there as long as it takes, even if talks drag on all night.

About 600 employees of the door-to-door transit service for people unable to navigate the conventional transit system have been on strike since last Tuesday, pausing service for all but essential medical trips.

Hundreds of drivers rallied outside TransLink’s head office earlier this week, calling for the transportation provider to intervene in the dispute with Transdev, which was contracted to oversee HandyDART service.

Transdev said earlier this week that it will provide a reply to the union’s latest proposal on Thursday.

A statement from the company said it “strongly believes” that their employees deserve fair wages, and that a fair contract “must balance the needs of their employees, clients and taxpayers.”

This report by The Canadian Press was first published Sept. 12, 2024.

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

Transat AT reports $39.9M Q3 loss compared with $57.3M profit a year earlier

Published

 on

 

MONTREAL – Travel company Transat AT Inc. reported a loss in its latest quarter compared with a profit a year earlier as its revenue edged lower.

The parent company of Air Transat says it lost $39.9 million or $1.03 per diluted share in its quarter ended July 31.

The result compared with a profit of $57.3 million or $1.49 per diluted share a year earlier.

Revenue in what was the company’s third quarter totalled $736.2 million, down from $746.3 million in the same quarter last year.

On an adjusted basis, Transat says it lost $1.10 per share in its latest quarter compared with an adjusted profit of $1.10 per share a year earlier.

Transat chief executive Annick Guérard says demand for leisure travel remains healthy, as evidenced by higher traffic, but consumers are increasingly price conscious given the current economic uncertainty.

This report by The Canadian Press was first published Sept. 12, 2024.

Companies in this story: (TSX:TRZ)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Trending